Cannabigerolic acid (CBGA)

Cannabigerolic acid (CBGA), the 2-carboxylic acid form of cannabigerol (CBG), is the central biosynthetic precursor from which all major phytocannabinoids are enzymatically derived in Cannabis sativa. Designated the "mother cannabinoid," CBGA is synthesized in the glandular trichomes of the cannabis plant through the geranylation of olivetolic acid by the membrane-bound aromatic prenyltransferase CsPT4 and subsequently serves as the common substrate for three FAD-dependent oxidocyclase enzymes: THCA synthase, CBDA synthase, and CBCA synthase. The compound was first isolated in the 1960s by Gaoni and Mechoulam at the Weizmann Institute of Science, and its role as the gateway intermediate in cannabinoid biosynthesis was formally established by Shoyama and colleagues in 1975. Despite its foundational position in phytocannabinoid metabolism, CBGA has received substantially less pharmacological attention than its neutral decarboxylation product CBG and the downstream cannabinoids THC and CBD; however, a rapidly expanding preclinical literature beginning approximately 2018 has identified a multi-target pharmacological profile that is distinct from and in several respects more potent than that of the neutral cannabinoids.

The principal characterized molecular targets of CBGA include the transient receptor potential melastatin 7 (TRPM7) ion channel, where CBGA is the most potent inhibitor among tested cannabinoids (IC50 approximately 1.8 micromolar extracellularly, 407 nanomolar intracellularly) through a mechanism requiring a functional kinase domain; the peroxisome proliferator-activated receptors alpha and gamma (PPARalpha/gamma), at which CBGA acts as a dual agonist with metabolic effects comparable to rosiglitazone in cell-based assays; the amyloidogenic enzyme beta-secretase 1 (BACE-1), inhibited with an IC50 of 1.4 micromolar; acetylcholinesterase (AChE, Ki 10.5 micromolar, competitive) and butyrylcholinesterase (BuChE, Ki 23.3 micromolar, noncompetitive); cyclooxygenase-1 and cyclooxygenase-2, each inhibited by approximately 30 percent at 62.5 micromolar; and the transient receptor potential channels TRPV3 and TRPV4, at which CBGA acts as a desensitizing modulator. CBGA also functions as a non-competitive antagonist at GPR55, blocks store-operated calcium entry, and inhibits amyloid-beta fibril formation with an IC50 of approximately 48 micromolar. The compound exhibits minimal direct affinity for cannabinoid CB1 and CB2 receptors, consistent with its non-psychoactive character.

In preclinical epilepsy models, CBGA exhibits divergent activity: it is anticonvulsant in the Scn1a+/- (Dravet syndrome) hyperthermia-induced seizure model and in the maximal electroshock threshold test at 30 to 100 mg/kg, and it potentiates the anticonvulsant effect of clobazam synergistically, but it is proconvulsant in the 6-Hz threshold model and at high chronic doses increases spontaneous seizure frequency. In an amyloid-beta-challenged mouse model of Alzheimer's disease, repeated CBGA administration at 10 mg/kg intraperitoneally restored cognitive recognition, reduced depressive-like behavior, increased hippocampal long-term potentiation amplitude to 174 percent of baseline, and normalized TRPM7 expression. CBGA-rich cannabis fractions have demonstrated selective cytotoxicity against colon cancer cell lines (IC50 approximately 8.2 micrograms per milliliter in SW-620 cells) with the strongest reactive oxygen species reduction among tested cannabinoids. Pharmacokinetic data remain limited; the compound is rapidly absorbed (tmax approximately 30 minutes in mouse plasma), exhibits poor brain penetration relative to plasma, and is chemically unstable owing to facile non-enzymatic decarboxylation to CBG at temperatures above 110 degrees Celsius or upon prolonged storage, a liability that has motivated prodrug strategies including the CBGA methyl ester. No human clinical trials of isolated CBGA have been completed; the compound is available as a research-grade certified reference material from multiple suppliers and is classified as non-psychoactive with no scheduled status independent of the cannabis plant matrix in most jurisdictions. This monograph reviews the biosynthesis, structural chemistry, multi-target molecular pharmacology, preclinical evidence across epilepsy, neurodegeneration, metabolic disease, and cancer indications, pharmacokinetic limitations, sourcing and handling considerations, and a comparative assessment of five non-psychoactive cannabinoid candidates against CBGA on five competency standards.